155 related articles for article (PubMed ID: 18393777)
1. Recent clinical trials of cladribine in hematological malignancies and autoimmune disorders.
Robak T; Wierzbowska A; Robak E
Rev Recent Clin Trials; 2006 Jan; 1(1):15-34. PubMed ID: 18393777
[TBL] [Abstract][Full Text] [Related]
2. Older and new formulations of cladribine. Pharmacology and clinical efficacy in hematological malignancies.
Robak T; Korycka A; Robak E
Recent Pat Anticancer Drug Discov; 2006 Jan; 1(1):23-38. PubMed ID: 18221024
[TBL] [Abstract][Full Text] [Related]
3. Purine nucleoside analogs as immunosuppressive and antineoplastic agents: mechanism of action and clinical activity.
Robak T; Lech-Maranda E; Korycka A; Robak E
Curr Med Chem; 2006; 13(26):3165-89. PubMed ID: 17168705
[TBL] [Abstract][Full Text] [Related]
4. Beyond hairy cell: the activity of cladribine in other hematologic malignancies.
Sigal DS; Miller HJ; Schram ED; Saven A
Blood; 2010 Oct; 116(16):2884-96. PubMed ID: 20634380
[TBL] [Abstract][Full Text] [Related]
5. 2-Chlorodeoxyadenosine: a potent antimetabolite with major activity in the treatment of indolent lymphoproliferative disorders.
Saven A; Piro LD
Hematol Cell Ther; 1996 Dec; 38 Suppl 2():S93-101. PubMed ID: 9137962
[TBL] [Abstract][Full Text] [Related]
6. Clinical and toxicological aspects of the antineoplastic drug cladribine: a review.
Guchelaar HJ; Richel DJ; Schaafsma MR
Ann Hematol; 1994 Nov; 69(5):223-30. PubMed ID: 7948311
[TBL] [Abstract][Full Text] [Related]
7. 2-Chlorodeoxyadenosine treatment in non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia resistant to conventional chemotherapy: results of a multicentric experience. International Society for Chemo-Immunotherapy.
Brugiatelli M; Holowiecka B; Dmoszynska A; Krieger O; Planinc-Peraica A; Labar B; Callea V; Morabito F; Jaksic B; Holowiecki J; Lutz D
Ann Hematol; 1996 Aug; 73(2):79-84. PubMed ID: 8774616
[TBL] [Abstract][Full Text] [Related]
8. High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias.
Betticher DC; Fey MF; von Rohr A; Tobler A; Jenzer H; Gratwohl A; Lohri A; Pugin P; Hess U; Pagani O
Ann Oncol; 1994 Jan; 5(1):57-64. PubMed ID: 7909685
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of cladribine (2-chlorodeoxyadenosine) in lymphoid malignancies. Cladribine Study Group.
Tobinai K; Ogura M; Hotta T; Kobayashi Y; Narabayashi M; Suzuki R; Kinoshita T; Kozuru M; Uike N; Ohashi Y
Jpn J Clin Oncol; 1997 Jun; 27(3):146-53. PubMed ID: 9255268
[TBL] [Abstract][Full Text] [Related]
10. Cladribine in the treatment of chronic lymphocytic leukemia.
Robak T
Leuk Lymphoma; 2001 Feb; 40(5-6):551-64. PubMed ID: 11426528
[TBL] [Abstract][Full Text] [Related]
11. Older and new purine nucleoside analogs for patients with acute leukemias.
Robak P; Robak T
Cancer Treat Rev; 2013 Dec; 39(8):851-61. PubMed ID: 23566572
[TBL] [Abstract][Full Text] [Related]
12. 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland.
Robak T; Błasińska-Morawiec M; Błoński J; Hellmann A; Hałaburda K; Konopka L; Kotlarek-Haus S; Potoczek S; Hansz J; Dmoszyńska A; Urasiński I; Zdziarska B; Dwilewicz-Trojaczek J; Hołowiecki J; Skotnicki AB
Eur J Haematol; 1999 Jan; 62(1):49-56. PubMed ID: 9918312
[TBL] [Abstract][Full Text] [Related]
13. Fewer infections, but maintained antitumor activity with lower-dose versus standard-dose cladribine in pretreated low-grade non-Hodgkin's lymphoma.
Betticher DC; von Rohr A; Ratschiller D; Schmitz SF; Egger T; Sonderegger T; Herrmann R; Kroner T; Zulian GB; Cavalli F; Fey MF; Cerny T
J Clin Oncol; 1998 Mar; 16(3):850-8. PubMed ID: 9508165
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of cladribine (2-chlorodeoxyadenosine) in relapsed or refractory adult T-cell leukemia-lymphoma.
Tobinai K; Uike N; Saburi Y; Chou T; Etoh T; Masuda M; Kawano F; Matsuoka M; Taguchi H; Makino T; Asano Y; Tamura K; Ohashi Y;
Int J Hematol; 2003 Jun; 77(5):512-7. PubMed ID: 12841391
[TBL] [Abstract][Full Text] [Related]
15. Cladribine for multiple sclerosis: review and current status.
Sipe JC
Expert Rev Neurother; 2005 Nov; 5(6):721-7. PubMed ID: 16274330
[TBL] [Abstract][Full Text] [Related]
16. Re-treatment with cladribine-based regimens in relapsed patients with B-cell chronic lymphocytic leukemia. Efficacy and toxicity in comparison with previous treatment.
Robak T; Boński JZ; Kasznicki M; Góra-Tybor J; Hellmann A; Konopka L; Dmoszyńska A; Dwilewicz-Trojaczek J; Wołowiec D;
Eur J Haematol; 2002 Jul; 69(1):27-36. PubMed ID: 12270059
[TBL] [Abstract][Full Text] [Related]
17. 2-Chlorodeoxyadenosine treatment of low-grade lymphomas.
Kay AC; Saven A; Carrera CJ; Carson DA; Thurston D; Beutler E; Piro LD
J Clin Oncol; 1992 Mar; 10(3):371-7. PubMed ID: 1346801
[TBL] [Abstract][Full Text] [Related]
18. Purine nucleoside analogues in the treatment of myleoid leukemias.
Robak T
Leuk Lymphoma; 2003 Mar; 44(3):391-409. PubMed ID: 12688309
[TBL] [Abstract][Full Text] [Related]
19. Purine nucleoside analogues for the treatment of hematological malignancies: pharmacology and clinical applications.
Robak T; Korycka A; Kasznicki M; Wrzesien-Kus A; Smolewski P
Curr Cancer Drug Targets; 2005 Sep; 5(6):421-44. PubMed ID: 16178817
[TBL] [Abstract][Full Text] [Related]
20. Cladribine for the treatment of hematologic malignancies.
Baltz JK; Montello MJ
Clin Pharm; 1993 Nov; 12(11):805-13; quiz 860-2. PubMed ID: 7903917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
